Farnesyl diphosphate synthase: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
Michal Harel (talk | contribs)
No edit summary
Line 2: Line 2:
<StructureSection load='2opm' size='350' side='right' scene='48/485622/Cv/15' caption='Human farnesyl diphosphate synthase complex with  lipophylic bisphosphonate inhibitor and Mg+2 ions (green) (PDB code [[2opm]]) '>
<StructureSection load='2opm' size='350' side='right' scene='48/485622/Cv/15' caption='Human farnesyl diphosphate synthase complex with  lipophylic bisphosphonate inhibitor and Mg+2 ions (green) (PDB code [[2opm]]) '>
__TOC__
__TOC__
'''Farnesyl pyrophosphate synthase''' (FPPS) is a chain elongation enzyme that catalyzes carbon-carbon formation in two consecutive condensation reactions that convert one equivalent of dimethylallyl diphosphate (DMAPP) and two equivalents of isopentyl diphosphates (IPP) into one equivalent of Farnesyl pyrophosphate (FPP). <ref>PMID:11152452</ref>In the first step, IPP and its isomer DMAPP react to form a ten-carbon geranyl diphosphate (GPP), while in the second step, the product geranyl diphosphate from the first step and an additional IPP molecule react to make FPP (see diagram). It is an essential enzyme in the biosynthesis of mevalonate, isoprenoids, and sterols in a variety of organisms. FFPS has been studied in conjunction with different parasites.  Bisphosphonates have been shown to inhibit FPPS and are currently being used for osteoporosis and the treatment of various bone diseases. Inhibition of FPPS in parasites such Trypanosoma cruzi (Tc), Trypanosoma brucei (Tb), Toxoplasma gondii and Leishmania major (Lm) displays antiparasitic activity which is being evaluated as putative therapeutics. <ref> PMID: 24598749</ref> <ref> PMID: 30926449</ref> <ref> PMID: 16835450</ref> <ref> PMID: 12089677</ref> <ref> PMID: 31296439 </ref> <ref>DOI: 10.1016/j.ijantimicag.2003.07.020</ref> <ref>DOI: 10.1074/jbc.M103950200</ref> <ref> DOI: 10.1128/AAC.46.3.929-931.2002</ref> <ref> DOI:10.1021/jm040132t</ref> <ref>DOI: 10.1021/jm0002578</ref> <ref>DOI:10.1021/jm0102809 </ref> <ref> DOI: 10.1128/AAC.01873-15</ref>  
'''Farnesyl pyrophosphate synthase''' or '''Farnesyl diphosphate synthase''' (FPPS) is a chain elongation enzyme that catalyzes carbon-carbon formation in two consecutive condensation reactions that convert one equivalent of dimethylallyl diphosphate (DMAPP) and two equivalents of isopentyl diphosphates (IPP) into one equivalent of Farnesyl pyrophosphate (FPP). <ref>PMID:11152452</ref>In the first step, IPP and its isomer DMAPP react to form a ten-carbon geranyl diphosphate (GPP), while in the second step, the product geranyl diphosphate from the first step and an additional IPP molecule react to make FPP (see diagram). It is an essential enzyme in the biosynthesis of mevalonate, isoprenoids, and sterols in a variety of organisms. FFPS has been studied in conjunction with different parasites.  Bisphosphonates have been shown to inhibit FPPS and are currently being used for osteoporosis and the treatment of various bone diseases. Inhibition of FPPS in parasites such Trypanosoma cruzi (Tc), Trypanosoma brucei (Tb), Toxoplasma gondii and Leishmania major (Lm) displays antiparasitic activity which is being evaluated as putative therapeutics. <ref> PMID: 24598749</ref> <ref> PMID: 30926449</ref> <ref> PMID: 16835450</ref> <ref> PMID: 12089677</ref> <ref> PMID: 31296439 </ref> <ref>DOI: 10.1016/j.ijantimicag.2003.07.020</ref> <ref>DOI: 10.1074/jbc.M103950200</ref> <ref> DOI: 10.1128/AAC.46.3.929-931.2002</ref> <ref> DOI:10.1021/jm040132t</ref> <ref>DOI: 10.1021/jm0002578</ref> <ref>DOI:10.1021/jm0102809 </ref> <ref> DOI: 10.1128/AAC.01873-15</ref>  


== Function  ==
== Function  ==

Revision as of 06:41, 25 July 2021

Introduction

Human farnesyl diphosphate synthase complex with lipophylic bisphosphonate inhibitor and Mg+2 ions (green) (PDB code 2opm)

Drag the structure with the mouse to rotate

References